Aurinia Pharmaceuticals Inc. (AUPH)Healthcare | Biotechnology | Edmonton, Canada | NasdaqGM
16.36 USD
-0.19
(-1.148%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:29 a.m. EDT
Aurinia Pharmaceuticals presents a compelling asymmetric setup where strong fundamental recovery meets speculative optimism. The company has successfully navigated a multi-year downturn, posting a massive +61% gain last year and ending the nine-year window with a +137% cumulative return. Fundamentals are robust, boasting a 76% gross margin, 56% operating margin, and a fortress balance sheet with minimal debt and significant free cash flow. The recent surge in institutional ownership and the CEO's massive $12.5 million purchase signal deep insider confidence in the turnaround strategy. However, the short-term outlook remains volatile. The stock is trading near its 52-week low, suggesting the market is still pricing in significant risk despite the improving metrics. The statistical forecast model indicates a slight negative lean for the next 45 days, creating a tension between the strong long-term thesis and potential near-term consolidation. This disconnect creates a high-conviction entry opportunity for patient investors willing to ride out the volatility. With no dividend to complicate the picture, the entire investment case rests on capital appreciation driven by the company's ability to execute its pipeline strategy. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.033808 |
| AutoTheta | 0.070277 |
| AutoETS | 0.070290 |
| MSTL | 0.070808 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 60% |
| H-stat | 2.29 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.453 |
| Excess Kurtosis | -0.65 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.431 |
| Revenue per Share | 2.368 |
| Market Cap | 2,176,717,312 |
| Trailing P/E | 7.18 |
| Forward P/E | 15.34 |
| Beta | 1.61 |
| Profit Margins | 100.84% |
| Website | https://www.auriniapharma.com |
As of Oct. 10, 2026, 9:29 a.m. EDT: Speculators are positioning for a moderate upside move over the next few months, evidenced by heavy open interest in out-of-the-money calls (strikes 20 and 25) relative to puts. While there is some defensive put buying at lower strikes, the volume and open interest concentration in the call side suggests a bullish bias for a rally toward the $20 level, likely driven by upcoming catalysts or earnings expectations.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.44289446 |
| Address1 | #140, 14315 – 118 Avenue |
| All Time High | 33.972 |
| All Time Low | 1.41 |
| Ask | 17.28 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 791,420 |
| Average Daily Volume3 Month | 963,277 |
| Average Volume | 963,277 |
| Average Volume10Days | 791,420 |
| Beta | 1.611 |
| Bid | 12.84 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 4.626 |
| City | Edmonton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.36 |
| Current Ratio | 5.419 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 16.58 |
| Day Low | 16.21 |
| Debt To Equity | 10.431 |
| Display Name | Aurinia Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,772,112,600 |
| Earnings Call Timestamp Start | 1,772,112,600 |
| Earnings Growth | 0.755 |
| Earnings Quarterly Growth | 0.739 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | 179,826,000 |
| Ebitda Margins | 0.57728 |
| Enterprise To Ebitda | 9.998 |
| Enterprise To Revenue | 5.771 |
| Enterprise Value | 1,797,830,144 |
| Eps Current Year | 0.944 |
| Eps Forward | 1.06667 |
| Eps Trailing Twelve Months | 2.28 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 250 708 4345 |
| Fifty Day Average | 16.1181 |
| Fifty Day Average Change | 0.2419014 |
| Fifty Day Average Change Percent | 0.01500806 |
| Fifty Two Week Change Percent | 44.289444 |
| Fifty Two Week High | 19.25 |
| Fifty Two Week High Change | -2.8899994 |
| Fifty Two Week High Change Percent | -0.15012984 |
| Fifty Two Week Low | 11.21 |
| Fifty Two Week Low Change | 5.1500006 |
| Fifty Two Week Low Change Percent | 0.4594113 |
| Fifty Two Week Range | 11.21 - 19.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,409,751,000,000 |
| Float Shares | 129,216,633 |
| Forward Eps | 1.06667 |
| Forward P E | 15.337454 |
| Free Cashflow | 147,817,120 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 128 |
| Fullday Change | -0.18999863 |
| Fullday Change Percent | -1.148028 |
| Fullday Price | 16.36 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.77884 |
| Gross Profits | 242,614,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06792 |
| Held Percent Institutions | 0.60557 |
| Implied Shares Outstanding | 133,051,168 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.isotechnika.com/for_investors/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada. |
| Long Name | Aurinia Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 2,176,717,312 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_882669 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 314,113,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,217,962,970 |
| Number Of Analyst Opinions | 7 |
| Open | 16.46 |
| Operating Cashflow | 175,243,008 |
| Operating Margins | 0.55685 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 250 744 2487 |
| Previous Close | 16.55 |
| Price Eps Current Year | 17.33051 |
| Price Hint | 2 |
| Price To Book | 3.5365329 |
| Price To Sales Trailing12 Months | 6.9876995 |
| Profit Margins | 1.0083699 |
| Quick Ratio | 4.857 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.189999 |
| Regular Market Change Percent | -1.14803 |
| Regular Market Day High | 16.58 |
| Regular Market Day Low | 16.21 |
| Regular Market Day Range | 16.21 - 16.58 |
| Regular Market Open | 16.46 |
| Regular Market Previous Close | 16.55 |
| Regular Market Price | 16.36 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 1,137,611 |
| Return On Assets | 0.15489 |
| Return On Equity | 0.66117996 |
| Revenue Growth | 0.189 |
| Revenue Per Share | 2.368 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 133,051,168 |
| Shares Percent Shares Out | 0.059499998 |
| Shares Short | 7,920,606 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 8,978,748 |
| Short Name | Aurinia Pharmaceuticals Inc |
| Short Percent Of Float | 0.0657 |
| Short Ratio | 9.71 |
| Source Interval | 15 |
| State | AB |
| Symbol | AUPH |
| Target High Price | 21.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 17.85714 |
| Target Median Price | 17.0 |
| Total Cash | 443,023,008 |
| Total Cash Per Share | 3.33 |
| Total Debt | 64,136,000 |
| Total Revenue | 311,507,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.28 |
| Trailing P E | 7.175439 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.55945 |
| Two Hundred Day Average Change | 0.80055046 |
| Two Hundred Day Average Change Percent | 0.051451076 |
| Type Disp | Equity |
| Volume | 1,137,611 |
| Website | https://www.auriniapharma.com |
| Zip | T5L 4S6 |